| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hemant Goyal, Hamza H Awad, Jalal K Ghal. Role of cannabis in cardiovascular disorders. Journal of thoracic disease. vol 9. issue 7. 2020-09-29. PMID:28840009. |
cannabinoids, or the active compounds of cannabis, have been shown to have heterogeneous effects on central and peripheral circulation. |
2020-09-29 |
2023-08-13 |
Not clear |
| Thomas B Strous. Cannabinoids in Medical Practice. Cannabis and cannabinoid research. vol 1. issue 1. 2020-09-29. PMID:28861478. |
there are two fda-approved cannabinoid products, whereas medical marijuana purchased at legal dispensaries is not fda regulated and may contain uncertain concentrations of various compounds. |
2020-09-29 |
2023-08-13 |
Not clear |
| Erin M Rock, Martin A Sticht, Cheryl L Limebeer, Linda A Parke. Cannabinoid Regulation of Acute and Anticipatory Nausea. Cannabis and cannabinoid research. vol 1. issue 1. 2020-09-29. PMID:28861486. |
the pre-clinical evidence points to a compelling need to evaluate the antinausea potential of cannabidiol, cannabidiolic acid, and treatments that boost the functioning of the endocannabinoid system in human clinical trials. |
2020-09-29 |
2023-08-13 |
human |
| Franjo Grotenhermen, Ethan Russo, Antonio Waldo Zuard. Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and cannabinoid research. vol 2. issue 1. 2020-09-29. PMID:28861499. |
these authors found that cannabidiol (cbd), a major cannabinoid of the cannabis plant devoid of psychotropic effects and of great interest for therapeutic use in several medical conditions, may be converted in gastric fluid into the psychoactive cannabinoids delta-8-thc and delta-9-thc to a relevant degree. |
2020-09-29 |
2023-08-13 |
Not clear |
| Bryson C Lochte, Alexander Beletsky, Nebiyou K Samuel, Igor Gran. The Use of Cannabis for Headache Disorders. Cannabis and cannabinoid research. vol 2. issue 1. 2020-09-29. PMID:28861505. |
this review considers historical prescription practices, summarizes the existing reports on the use of cannabis for headache, and examines the preclinical literature exploring the role of exogenous and endogenous cannabinoids to alter headache pathophysiology. |
2020-09-29 |
2023-08-13 |
Not clear |
| Gerhard Nahler, Franjo Grotenhermen, Antonio Waldo Zuardi, José A S Cripp. A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. Cannabis and cannabinoid research. vol 2. issue 1. 2020-09-29. PMID:28861507. |
cannabidiol (cbd), a major cannabinoid of hemp, does not bind to cb1 receptors and is therefore devoid of psychotomimetic properties. |
2020-09-29 |
2023-08-13 |
Not clear |
| Leslie Grayson, Brannon Vines, Kate Nichol, Jerzy P Szaflarsk. An interaction between warfarin and cannabidiol, a case report. Epilepsy & behavior case reports. vol 9. 2020-09-29. PMID:29387536. |
•an interaction between warfarin and cannabidiol is described•the mechanisms of cannabidiol and warfarin metabolism are reviewed•mechanism of the interaction is proposed•inr should be monitored in patients when cannabinoids are introduced. |
2020-09-29 |
2023-08-13 |
Not clear |
| Jeet J Mehta, Arjun K Mahendran, Ravi K Bajaj, Arpan R Dosh. Myocardial Ischemia with Cannabinoid Use in an Adolescent. Cureus. vol 9. issue 11. 2020-09-29. PMID:29399427. |
this case report raises concern about cardiac ischemia related to synthetic cannabinoid abuse in the pediatric population in the current era of cannabis legalization. |
2020-09-29 |
2023-08-13 |
Not clear |
| Nathan J Kolla, Achal Mishr. The Endocannabinoid System, Aggression, and the Violence of Synthetic Cannabinoid Use, Borderline Personality Disorder, Antisocial Personality Disorder, and Other Psychiatric Disorders. Frontiers in behavioral neuroscience. vol 12. 2020-09-29. PMID:29636670. |
while most human research has concluded that the active ingredient of marijuana, Δ9-tetrahydrocannabinol, tends to dampen rather than provoke aggression in acute doses, recent evidence supports a relationship between the ingestion of synthetic cannabinoids and emergence of violent or aggressive behavior. |
2020-09-29 |
2023-08-13 |
human |
| Dusan Kola. Addictive potential of novel treatments for refractory depression and anxiety. Neuropsychiatric disease and treatment. vol 14. 2020-09-29. PMID:29928123. |
synthetic cannabinoids and medicinal cannabis are increasingly being prescribed for a number of medical conditions, including anxiety disorders, without enough evidence about their efficacy and with the risk of patients developing dependence. |
2020-09-29 |
2023-08-13 |
Not clear |
| Yara Mouhamed, Andrey Vishnyakov, Bessi Qorri, Manpreet Sambi, Sm Signy Frank, Catherine Nowierski, Anmol Lamba, Umrao Bhatti, Myron R Szewczu. Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. Drug, healthcare and patient safety. vol 10. 2020-09-29. PMID:29928146. |
also, we briefly highlight the current recommendations provided by canadian medical colleges on the parameters that need to be considered prior to authorizing mm use, routes of administration as well as a general overview of the endocannabinoid system as it pertains to cannabis. |
2020-09-29 |
2023-08-13 |
Not clear |
| Koby Cohen, Aviv M Weinstei. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Frontiers in public health. vol 6. 2020-09-29. PMID:29930934. |
synthetic cannabinoid products have effects similar to those of natural cannabis, yet, these drugs are more potent and dangerous, and have been associated with dangerous adverse effects. |
2020-09-29 |
2023-08-13 |
Not clear |
| Judith Klassen, Gail Wilso. Cannabinoid Hyperemesis Syndrome Masquerading as Uremia: An Educational Case Report. Canadian journal of kidney health and disease. vol 5. 2020-09-29. PMID:30159161. |
with marijuana legalization, clinicians need to be aware of cannabinoid hyperemesis syndrome (chs), which may masquerade as other disease states such as uremia. |
2020-09-29 |
2023-08-13 |
Not clear |
| Libor Uttl, Ewa Szczurowska, Kateřina Hájková, Rachel R Horsley, Kristýna Štefková, Tomáš Hložek, Klára Šíchová, Marie Balíková, Martin Kuchař, Vincenzo Micale, Tomáš Páleníče. Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ Frontiers in neuroscience. vol 12. 2020-09-29. PMID:30405327. |
behavioral and pharmacokinetic profile of indole-derived synthetic cannabinoids jwh-073 and jwh-210 as compared to the phytocannabinoid Δ synthetic cannabinoid compounds are marketed as "legal" marijuana substitutes, even though little is known about their behavioral effects in relation to their pharmacokinetic profiles. |
2020-09-29 |
2023-08-13 |
Not clear |
| Sonja Vučković, Dragana Srebro, Katarina Savić Vujović, Čedomir Vučetić, Milica Prostra. Cannabinoids and Pain: New Insights From Old Molecules. Frontiers in pharmacology. vol 9. 2020-09-29. PMID:30542280. |
the term 'medical cannabis' refers to physician-recommended use of the cannabis plant and its components, called cannabinoids, to treat disease or improve symptoms. |
2020-09-29 |
2023-08-13 |
Not clear |
| Bradley Kolb, Hamidreza Saber, Hassan Fadel, Gary Raja. The endocannabinoid system and stroke: A focused review. Brain circulation. vol 5. issue 1. 2020-09-29. PMID:31001593. |
finally, evidence for the role of cannabidiol, a publicly available cannabinoid that does not bind directly to known endocannabinoid receptors, as a stroke neuroprotectant is also reviewed. |
2020-09-29 |
2023-08-13 |
human |
| Aristides Tsatsakis, Anca Oana Docea, Daniela Calina, Konstantinos Tsarouhas, Laura-Maria Zamfira, Radu Mitrut, Javad Sharifi-Rad, Leda Kovatsi, Vasileios Siokas, Efthimios Dardiotis, Nikolaos Drakoulis, George Lazopoulos, Christina Tsitsimpikou, Panayiotis Mitsias, Monica Neag. A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse. Journal of clinical medicine. vol 8. issue 9. 2020-09-29. PMID:31450861. |
the major classes of drugs linked to stroke are cocaine, amphetamines, heroin, morphine, cannabis, and new synthetic cannabinoids, along with androgenic anabolic steroids (aass). |
2020-09-29 |
2023-08-13 |
Not clear |
| Dongmei Lyu, Rachel Backer, W George Robinson, Donald L Smit. Plant Growth-Promoting Rhizobacteria for Cannabis Production: Yield, Cannabinoid Profile and Disease Resistance. Frontiers in microbiology. vol 10. 2020-09-29. PMID:31456755. |
plant growth-promoting rhizobacteria for cannabis production: yield, cannabinoid profile and disease resistance. |
2020-09-29 |
2023-08-13 |
Not clear |
| Michael P Smoker, Maribel Hernandez, Yanping Zhang, Stephen L Boeh. Assessment of Acute Motor Effects and Tolerance Following Self-Administration of Alcohol and Edible ∆ Alcoholism, clinical and experimental research. vol 43. issue 11. 2020-09-28. PMID:31524960. |
assessment of acute motor effects and tolerance following self-administration of alcohol and edible ∆ cannabinoids and their principle psychoactive target, the cannabinoid type 1 receptor (cb1r), impact a number of alcohol-related properties, and although alcohol and cannabis are often co-used, particularly in adolescence, few animal models of this phenomenon exist. |
2020-09-28 |
2023-08-13 |
Not clear |
| Dirk W Lachenmeier, Patrick Die. A Warning against the Negligent Use of Cannabidiol in Professional and Amateur Athletes. Sports (Basel, Switzerland). vol 7. issue 12. 2020-09-28. PMID:31847307. |
cannabidiol (cbd) is a non-psychoactive cannabinoid, widely marketed to athletes for claimed effects such as decreased anxiety, fear memory extinction, anti-inflammatory properties, relief of pain and for post-exercise recovery. |
2020-09-28 |
2023-08-13 |
Not clear |